• 1
    Craig RG, Hunter JM. Neuromuscular blocking drugs and their antagonists in patients with organ disease. Anaesthesia 2009; 64(Suppl. 1): 5565.
  • 2
    Sorgenfrei IF, Norrild K, Larsen PB, et al. Reversal of rocuronium induced neuromuscular block by the selective relaxant binding agent sugammadex. Anesthesiology 2006; 104: 66774.
  • 3
    de Boer HD, Driessen JJ, van Egmond J, Booij LHDJ. Non-steroidal neuromuscular blocking agents to re-establish paralysis after reversal of rocuronium-induced neuromuscular block with sugammadex. Canadian Journal of Anesthesia 2008; 55: 1245.
  • 4
    Staals LM, Snoeck MM, Driessen JJ, et al. Multicentre, parallel-group, comparative trial evaluating the efficacy and safety of sugammadex in patients with end-stage renal failure or normal renal function. British Journal of Anaesthesia 2008; 101: 4927.
  • 5
    Staals LM, Snoeck MM, Driessen JJ, et al. Reduced clearance of rocuronium and sugammadex in patients with severe to end-stage renal failure: a pharmacokinetic study. British Journal of Anaesthesia 2010; 104: 319.
  • 6
    Cammu G, de Kam PJ, de Graeve K, et al. Repeat dosing of rocuronium 1.2−1 after reversal of neuromuscular block by sugammadex 4.0−1 in anaesthestized healthy volunteers: a modelling-based pilot study. British Journal of Anaesthesia 2010; 105: 48792.